JP2014530231A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530231A5
JP2014530231A5 JP2014535166A JP2014535166A JP2014530231A5 JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5 JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
container
mdi
metered dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535166A
Other languages
English (en)
Other versions
JP5818290B2 (ja
JP2014530231A (ja
Filing date
Publication date
Priority claimed from GB201117621A external-priority patent/GB201117621D0/en
Application filed filed Critical
Publication of JP2014530231A publication Critical patent/JP2014530231A/ja
Publication of JP2014530231A5 publication Critical patent/JP2014530231A5/ja
Application granted granted Critical
Publication of JP5818290B2 publication Critical patent/JP5818290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 界面活性剤を含まない医薬組成物であって、
    (a)硫酸サルブタモールからなる薬物成分と、
    (b)1,1−ジフルオロエタン(R−152a)から実質的になる噴射剤成分と、
    から実質的になる、医薬組成物。
  2. 極性賦形剤を含まない、請求項1に記載の医薬組成物。
  3. エタノールを含まない、請求項1に記載の医薬組成物。
  4. 前記噴射剤成分が完全にR−152aからなる、請求項1〜3のいずれか一項に記載の医薬組成物。
  5. 完全に成分(a)及び(b)からなる、請求項1〜4のいずれか一項に記載の医薬組成物。
  6. 請求項1〜5のいずれか一項に記載の医薬組成物を含む、密封容器。
  7. 定量噴霧式吸入器(MDI)と共に使用するための加圧容器である、請求項6に記載の密封容器。
  8. 請求項7に記載の加圧容器を装着した、定量噴霧式吸入器(MDI)。
  9. 硫酸サルブタモールからなる薬物成分と、1,1−ジフルオロエタン(R−152a)から実質的になる噴射剤成分の、呼吸器疾患を患うか又は患う可能性のある患者の治療のための、前記2つの成分から実質的になる、界面活性剤を含まない医薬組成物の製造における使用。
  10. 前記呼吸器疾患が喘息である、請求項9に記載の使用。
  11. 前記医薬組成物が定量噴霧式吸入器(MDI)を使用して患者に送達されるように適合されてなる、請求項9又は10に記載の使用。
  12. 呼吸器疾患を患うか又は患う可能性のある患者の治療に用いるための、請求項1〜5のいずれか一項に記載の医薬組成物。
  13. 前記呼吸器疾患が喘息である、請求項12に記載の医薬組成物。
  14. 前記医薬組成物が定量噴霧式吸入器(MDI)を使用して患者に送達されるように適合されてなる、請求項12又は13に記載の医薬組成物。
  15. 請求項1〜5のいずれか一項に記載の医薬組成物の製造方法であって、
    薬剤送達装置を使用して前記薬物成分が最終的にエアロゾルスプレーとして放出されることになる開放容器に、秤量した前記薬物成分を導入する工程と、
    前記容器にバルブ装置を装着する工程と、
    加圧下で前記バルブを通して前記容器に前記噴射剤成分を液形態で導入する工程と、
    を含む、方法。
JP2014535166A 2011-10-12 2012-10-12 硫酸サルブタモールを含有する組成物 Active JP5818290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201117621A GB201117621D0 (en) 2011-10-12 2011-10-12 Compositions
GB1117621.1 2011-10-12
PCT/GB2012/052542 WO2013054135A1 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Publications (3)

Publication Number Publication Date
JP2014530231A JP2014530231A (ja) 2014-11-17
JP2014530231A5 true JP2014530231A5 (ja) 2014-12-25
JP5818290B2 JP5818290B2 (ja) 2015-11-18

Family

ID=45091933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535166A Active JP5818290B2 (ja) 2011-10-12 2012-10-12 硫酸サルブタモールを含有する組成物

Country Status (12)

Country Link
US (1) US9114164B2 (ja)
EP (1) EP2766005B1 (ja)
JP (1) JP5818290B2 (ja)
CN (1) CN103857388B (ja)
AU (1) AU2012322453B2 (ja)
BR (1) BR112014008609B1 (ja)
CA (1) CA2851764C (ja)
ES (1) ES2556585T3 (ja)
GB (1) GB201117621D0 (ja)
MX (1) MX336225B (ja)
WO (1) WO2013054135A1 (ja)
ZA (1) ZA201402234B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3236967B1 (en) 2014-12-22 2019-10-16 SUDA Pharmaceuticals Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3701940A1 (en) 2015-12-04 2020-09-02 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN114712337A (zh) * 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
CA3037080C (en) * 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
ES2957459T3 (es) 2016-09-19 2024-01-19 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
AU2017328910B2 (en) * 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
FR3130554A1 (fr) 2021-12-20 2023-06-23 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
FR3137830A1 (fr) 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US7105152B1 (en) * 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
DK0617610T3 (da) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
ATE236617T1 (de) 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
EP1019020A1 (en) 1997-09-29 2000-07-19 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
PT1102579E (pt) 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
GB2392915B (en) 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process

Similar Documents

Publication Publication Date Title
JP2014530231A5 (ja)
JP2014528470A5 (ja)
Stein et al. The history of therapeutic aerosols: a chronological review
JP2007106777A5 (ja)
HRP20140582T4 (hr) Kombinacijska terapija za copd
CN106455705A (zh) 用于吸烟欲望救济的方法和装置
JP2009503104A5 (ja)
JP2009269923A5 (ja)
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
JP2013544781A5 (ja)
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
HRP20140550T1 (hr) Aerosolna formulacija za copd
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
PH12014502746A1 (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
NZ599900A (en) Pharmaceutical suspension aerosol formulations for use in metered dose inhalers
WO2012040228A3 (en) Aerosol composition for administering drugs
MX370890B (es) Composición que comprende sulfato de salbutamol.
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
GB201118188D0 (en) Manufacture of medicinal aerosol canisters
WO2011061498A3 (en) Inhalation solutions
JP2004529108A5 (ja)